End-stage kidney disease stage IV and V Urological and Genital Diseases Chronic kidney disease
Conditions
Interventions
The continuous rhythm monitoring of among the participants of the study was carried out using the Medtronic ICMs (Reveal® DX, Reveal XT™ and Reveal Linq™) (Medtronic Inc, Minneapolis, MN, USA). ICMs w
Sponsors
Päijät-Hämeen Keskussairaala
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Stage 4 (pre-dialysis, glomerular filtration rate 15-29 mL/min/1.73m²) or stage 5 (end-stage renal disease, <15 mL/min/1.73m² or dialysis) 2. Planned active treatment is either hemodialysis or peritoneal dialysis, or kidney transplantation. The hemodialysis also includes short daily home hemodialysis
Exclusion criteria
Exclusion criteria: 1. Age >75 years 2. Age <18 years 3. Presence of a non-cardiovascular and non-renal disease which limits the expected life-span to less than 1 year 4. Probable noncompliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence and burden of atrial fibrillation, atrial flutter, bradycardia, sustained and non-sustained ventricular tachycardia, ventricular premature contractions, asystole and ventricular fibrillation are quantified using the data from insertable cardiac monitors over the course of the follow-up time of 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Temporal association between dialysis and the arrhythmias using the data from insertable cardiac monitors over the course of the follow-up time of 3 years 2. Prevalence of arrhythmias using the data from insertable cardiac monitors over the course of the follow-up time of 3 years. 3. Survival at 3 years measured using patient records. | — |
Countries
Finland
Contacts
Public ContactJoonas Rautavaara
Outcome results
None listed